Table 2.
DAA regimens administered to hepatitis C virus (HCV) positive patients according to their genotype.
| Regimens | Total | GT1 | GT2 | GT3 | GT6 | GT unknown or mixed |
|---|---|---|---|---|---|---|
| SOF + RBV | 162 (32.79) | 41 (14.37) | 76 (83.52) | 22 (68.75) | 5 (71.43) | 9 (100) |
| SOF + DCV ± RBV | 41 (8.30) | 14 (3.94) | 15 (16.48) | 10 (31.25) | 2 (28.57) | 0 (0.00) |
| EBR/GZR | 64 (12.96) | 63 (17.75) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| OBV/PTV/r/DSV ± RBV | 212 (42.91) | 212 (59.72) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| DCV + ASV | 15 (3.04) | 15 (4.23) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
Data expressed as sample size and proportion (%).
DAAs, direct-acting antiviral agents; HCV, hepatitis C virus; GT, genotype; SOF, sofosbuvir; RBV, ribavirin; DCV, daclatasvir; EBR/GZR, elbasvir/grazoprevir; OBV/PTV/r/DSV, ombitasvir/paritaprevir/ritonavir and dasabuvir; ASV, asunaprevir.